Renal cell carcinoma (RCC) is the most common type of kidney cancer, occurring in about 9 out of 10 kidney cancer cases. The most common subtype of RCC is clear-cell RCC, followed by non-clear cell histologies such as papillary and chromophobe, which are associated with poorer prognosis. Both targeted therapies and immunotherapies have been highly successful in RCC, with the successes of 1st-line IO-TKI combinations signaling a third breakthrough after the earlier breakthroughs of targeted agents and checkpoint inhibitors individually.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in renal cell carcinoma to help guide strategic and tactical commercial development decisions for market participants.